The growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, has announced a new contract with Sedana Medical worth €2.5m. Venn will carry out a randomised, controlled, open label Phase III study to confirm efficacy and safety of sedation with isoflurane in ventilated ICU patients. This trial is confined to patients in Germany and commences immediately.
08 Nov 2016
€2.5m phase III contract to commence this year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
€2.5m phase III contract to commence this year
hVIVO plc (HVO:LON) | 26.5 -0.1 (-2.0%) | Mkt Cap: 180.3m
- Published:
08 Nov 2016 -
Author:
Derren Nathan -
Pages:
6
The growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, has announced a new contract with Sedana Medical worth €2.5m. Venn will carry out a randomised, controlled, open label Phase III study to confirm efficacy and safety of sedation with isoflurane in ventilated ICU patients. This trial is confined to patients in Germany and commences immediately.